AEMD
Aethlon Medical, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+22/100
Last price
6.09
▼ 0.44 (6.67%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
6.53
Day high
6.51
Day low
6.09
Volume
75.72K
Market cap
$9.77M
P/E (TTM)
—
52W range
1.41 – 38.50
Trailing performance
Returnvs SPY
1W
-4.55%
-6.5%
1M
+234.62%
+233.5%
3M
+76.52%
+72.0%
6M
-41.72%
-59.9%
YTD
-56.03%
-70.3%
1Y
-84.58%
-101.0%
3Y
-99.34%
-181.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
16 more panels on AEMD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+1.68M
Net buying
Buy transactions
36
1.71M shares
Sell transactions
1
26.85K shares
Net transactions
+37
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
4.10K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Apr 17, 26 | BROENNIMAN EDWARD G Director |
STOCK | 21.82K | $49.96K | Direct |
| Apr 17, 26 | ROSSETTI ANGELA Director |
STOCK | 21.82K | $49.96K | Direct |
| Apr 17, 26 | SHAH CHETAN S Director |
STOCK | 21.82K | $49.96K | Direct |
| Apr 17, 26 | GIKAKIS NICOLAS Director |
STOCK | 21.82K | $49.96K | Direct |
| Apr 23, 25 | BROENNIMAN EDWARD G Director |
STOCK | 142.86K | $50.00K | Direct |
| Apr 23, 25 | ROSSETTI ANGELA Director |
STOCK | 142.86K | $50.00K | Direct |
| Apr 23, 25 | SHAH CHETAN S Director |
STOCK | 142.86K | $51.14K | Direct |
| Apr 23, 25 | GIKAKIS NICOLAS Director |
STOCK | 142.86K | $50.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BROENNIMAN EDWARD G |
Director | 23.45K | Stock Award(Grant) |
GIKAKIS NICOLAS |
Director | 22.84K | Stock Award(Grant) |
ROSSETTI ANGELA |
Director | 26.21K | Stock Award(Grant) |
SHAH CHETAN S |
Director | 23.02K | Stock Award(Grant) |
Fundamentals
Market cap$9.77M
Enterprise value$-235.15K
Revenue (TTM)—
Gross profit—
EBITDA$-6.77M
Net income$-6.94M
EPS (TTM)$-32.97
Free cash flow$-4.79M
Total cash$4.93M
Total debt$367.61K
Book value / share$10.89
Shares outstanding1.60M
Float702.05K
Short % of float4.67%
Dividend yield0.00%
Beta (5Y)1.21
Valuation & profitability ratios
Trailing P/E—
Forward P/E-10.68
PEG ratio—
Price / sales—
Price / book0.56
EV / revenue—
EV / EBITDA0.04
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-160.91%
Return on assets-76.69%
Debt / equity7.07
Current ratio5.42
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $574.25K | — |
| Operating revenue | $0 | $0 | $0 | $574.25K | — |
| Selling, general & admin | $7.29M | $9.34M | $12.64M | $12.47M | -21.9% |
| Total operating expense | $7.29M | $9.34M | $12.64M | $12.47M | -21.9% |
| Operating income | -$7.29M | -$9.34M | -$12.64M | -$11.90M | +21.9% |
| Net interest income | $142.16K | $288.01K | $447.36K | $10.97K | -50.6% |
| Pre-tax income | -$7.15M | -$13.39M | -$12.21M | -$12.03M | +46.6% |
| Net income | -$7.15M | -$13.39M | -$12.21M | -$12.03M | +46.6% |
| Net income to common | -$7.15M | -$13.39M | -$12.21M | -$12.03M | +46.6% |
| Basic EPS | -53.05 | -428.85 | -1,944.00 | -2,360.00 | +87.6% |
| Diluted EPS | -53.05 | -428.85 | -1,944.00 | -2,360.00 | +87.6% |
| EBIT | -$7.14M | -$13.38M | -$12.64M | -$11.90M | +46.7% |
| EBITDA | -$6.81M | -$13.04M | -$12.28M | -$11.66M | +47.7% |
| Basic shares | 134.79K | 31.22K | 6.28K | 5.13K | +331.8% |
| Diluted shares | 134.79K | 31.22K | 6.28K | 5.13K | +331.8% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.03M | $5.50M | $5.44M | $14.53M | — | -8.6% |
| Cash & short-term investments | $5.03M | $5.50M | $5.44M | $14.53M | — | -8.6% |
| Accounts receivable | — | — | — | $0 | $127.97K | — |
| Total current assets | $5.57M | $5.95M | $6.23M | $15.09M | — | -6.4% |
| Property, plant & equipment | $664.64K | $1.28M | $1.90M | $2.30M | — | -48.0% |
| Goodwill & intangibles | $0 | $550 | $1.10K | $1.65K | — | -100.0% |
| Total assets | $6.33M | $7.36M | $8.25M | $17.51M | — | -13.9% |
| Total current liabilities | $1.45M | $1.90M | $1.83M | $1.51M | — | -23.8% |
| Total debt | $336.72K | $649.75K | $940.32K | $1.21M | — | -48.2% |
| Total liabilities | $1.45M | $2.24M | $2.48M | $2.44M | — | -35.3% |
| Retained earnings | -$175.11M | -$167.95M | -$154.57M | -$142.36M | — | -4.3% |
| Shareholder equity | $4.89M | $5.12M | $5.77M | $15.06M | — | -4.6% |
| Working capital | $4.12M | $4.05M | $4.40M | $13.59M | — | +1.8% |
| Net tangible assets | $4.89M | $5.12M | $5.77M | $15.06M | — | -4.6% |
| Shares issued | 1.57M | 258.52K | 32.87K | 28.74K | — | +507.5% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$7.15M | -$13.39M | -$12.21M | -$12.03M | — | +46.6% |
| Depreciation & amortisation | $323.65K | $339.56K | $359.06K | $240.89K | — | -4.7% |
| Stock-based compensation | $278.55K | $415.23K | $1.22M | $1.05M | — | -32.9% |
| Change in working capital | -$743.15K | $93.69K | $478.66K | $65.34K | — | -893.2% |
| Operating cash flow | -$7.00M | -$7.65M | -$10.13M | -$10.51M | — | +8.5% |
| Capital expenditure | -$3.70K | — | -$250.87K | -$943.11K | -$349.19K | — |
| Investing cash flow | -$3.70K | $0 | -$250.87K | -$943.11K | — | — |
| Financing cash flow | $6.52M | $7.73M | $1.29M | $8.91M | — | -15.6% |
| Free cash flow | -$7.00M | -$7.65M | -$10.38M | -$11.45M | — | +8.4% |
| End cash position | $5.13M | $5.60M | $5.53M | $14.62M | — | -8.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | — | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | — | $0 | $0 | $0 | $0 | $0 | — |
| Selling, general & admin | — | $1.93M | $2.06M | $1.51M | $1.79M | $2.00M | — |
| Total operating expense | — | $1.93M | $2.06M | $1.51M | $1.79M | $2.00M | — |
| Operating income | — | -$1.93M | -$2.06M | -$1.51M | -$1.79M | -$2.00M | — |
| Net interest income | — | $45.03K | $43.87K | $22.73K | $36.47K | $83.81K | — |
| Pre-tax income | — | -$1.88M | -$2.02M | -$1.49M | -$1.76M | -$6.25M | — |
| Net income | — | -$1.88M | -$2.02M | -$1.49M | -$1.76M | -$6.25M | — |
| Net income to common | — | -$1.88M | -$2.02M | -$1.49M | -$1.76M | -$6.25M | — |
| Basic EPS | -4.02 | — | -12.25 | -18.70 | -42.42 | — | — |
| Diluted EPS | -4.02 | — | -12.25 | -18.70 | -42.42 | — | — |
| EBIT | — | -$1.77M | -$2.06M | -$1.51M | -$1.79M | -$6.04M | — |
| EBITDA | — | -$1.69M | -$1.98M | -$1.43M | -$1.71M | -$5.96M | — |
| Basic shares | 384.70K | — | 164.63K | 79.50K | 41.53K | — | — |
| Diluted shares | 384.70K | — | 164.63K | 79.50K | 41.53K | — | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.03M | $6.96M | $5.85M | $3.77M | $5.50M | -27.7% |
| Cash & short-term investments | $5.03M | $6.96M | $5.85M | $3.77M | $5.50M | -27.7% |
| Total current assets | $5.57M | $7.14M | $6.25M | $4.05M | $5.95M | -22.0% |
| Property, plant & equipment | $664.64K | $816.76K | $970.49K | $1.12M | $1.28M | -18.6% |
| Goodwill & intangibles | $0 | $138 | $275 | $413 | $550 | -100.0% |
| Total assets | $6.33M | $8.06M | $7.32M | $5.31M | $7.36M | -21.4% |
| Total current liabilities | $1.45M | $1.26M | $1.40M | $1.63M | $1.90M | +15.1% |
| Total debt | $336.72K | $417.52K | $496.77K | $573.85K | $649.75K | -19.4% |
| Total liabilities | $1.45M | $1.34M | $1.58M | $1.88M | $2.24M | +7.6% |
| Retained earnings | -$175.11M | -$173.22M | -$171.20M | -$169.72M | -$167.95M | -1.1% |
| Shareholder equity | $4.89M | $6.71M | $5.75M | $3.42M | $5.12M | -27.2% |
| Working capital | $4.12M | $5.88M | $4.85M | $2.42M | $4.05M | -29.9% |
| Net tangible assets | $4.89M | $6.71M | $5.75M | $3.42M | $5.12M | -27.2% |
| Shares issued | 1.57M | 973.21K | 761.32K | 317.32K | 258.52K | +61.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$1.88M | -$2.02M | -$1.49M | -$1.76M | -$6.25M | +6.6% |
| Depreciation & amortisation | $79.55K | $81.60K | $79.87K | $82.64K | $83.86K | -2.5% |
| Stock-based compensation | $61.22K | $72.44K | $72.44K | $72.44K | $72.44K | -15.5% |
| Change in working capital | -$81.65K | -$84.07K | -$397.00K | -$180.43K | -$258.39K | +2.9% |
| Operating cash flow | -$1.75M | -$1.87M | -$1.66M | -$1.71M | -$1.67M | +6.6% |
| Capital expenditure | -$2.05K | — | — | — | — | — |
| Investing cash flow | -$2.05K | — | — | — | $2.19K | — |
| Financing cash flow | -$196.50K | $2.98M | $3.74M | -$5.36K | $2.36M | -106.6% |
| Free cash flow | -$1.75M | -$1.88M | -$1.66M | -$1.71M | -$1.67M | +6.6% |
| End cash position | $5.13M | $7.06M | $5.95M | $3.86M | $5.60M | -27.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -4.05 | -4.02 | +0.7% |
| Mar 2026 | -12.28 | — | — |
| Dec 2025 | -10.05 | -12.25 | -21.9% |
| Sep 2025 | -8.48 | -18.70 | -120.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -2.91 | 2 | $0 | 0.0% |
| Next quarter | -1.15 | 2 | $0 | 0.0% |
| Current year | -5.74 | 2 | $0 | 0.0% |
| Next year | -0.57 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$13.25
High target$25.00
Low target$1.50
Implied upside117.57%
Analyst count2
ConsensusHOLD
Strong buy / Buy0 / 0
Hold2
Sell / Strong sell0 / 0
Held by insiders0.58%
Held by institutions4.34%
Institutions holding16
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
6.48
-6.08% from price
SMA 20
5.00
+21.75% from price
SMA 50
3.61
+68.89% from price
SMA 100
5.46
+11.52% from price
SMA 200
8.48
-28.22% from price
EMA 12
5.99
+1.75% from price
EMA 26
5.01
+21.50% from price
EMA 50
4.61
+32.18% from price
RSI (14)
64.0
Neutral
MACD (12,26,9)
0.97
Hist 0.04
ATR (14)
1.09
17.87% of price
Realised vol 30D
460.3%
Annualised
Bollinger upper
9.55
20, 2σ
Bollinger lower
0.45
20, 2σ
50 / 200 cross
Death
3.61 vs 8.48
Trend bias
Below 200
-28.22%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
4.37
More volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
460.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-96.3%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
1.09
17.87% of price
Beta (reported)
1.21
5Y monthly, from filing
Short interest
Shares short
74.85K
Prior 65.08K
Change vs prior
+15.0%
Shorts adding
% of float
4.67%
Normal
% of shares out
4.67%
Against total outstanding
Days to cover
0.0
Liquid
Float
702.05K
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Mar 10, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 30, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 24, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 4, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 24, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateOct 15, 2019
Last split1:5
Split dateAug 4, 2026
SEC filings
Corporate Changes & Voting Matters
8-K/A · 2026-10-05
Corporate Changes & Voting Matters
8-K · 2026-10-01
Corporate Changes & Voting Matters
8-K · 2026-09-17
Corporate Changes & Voting Matters
8-K · 2026-09-15
Proxy Statements
DEFA14A · 2026-09-04
Proxy Statements
DEF 14A · 2026-09-01
Corporate Changes & Voting Matters
8-K · 2026-08-31
Proxy Statements
PRE 14A · 2026-08-21
Headlines
BC-Most Active Stocks
Associated Press · 20d ago
Aethlon Medical Shares Surge Over 400% After Announcing North Immunology Merger
InvestorsHub · 20d ago
North Immunology joins biotech reverse merger boom with Aethlon deal
BioPharma Dive · 20d ago
Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
PR Newswire · 20d ago
BC-Most Active Stocks
Associated Press · 40d ago
AEMD: Oncology Study Advances; Cost-Efficient Preclinical Activities Regarding Other Diseases Continue
Zacks Small Cap Research · 49d ago
Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream
GlobeNewswire · 50d ago
Aethlon Medical, Inc. Q1 2027 Earnings Call Summary
Moby · 54d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.